CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...

However, the European Medicines Agency (EMA), against all odds, has refused to authorize its marketing. After almost two years of trying to get the agency to see reason, PharmaMar sued the ...

The increasing use of diabetes drug Ozempic as a weight-loss treatment prompted the European Medicines Agency to urge doctors to prioritize the injection made by Novo Nordisk A/S for diabetics ...

The European Medicines Agency also said that extra doses of the Moderna and Pfizer-BioNTech vaccines could be given to people with underlying health conditions as early as 28 days after a second dose.